Hepatitis C virus clearance and less liver damage in patients with high cholesterol, low-density lipoprotein cholesterol and APOE ε4 allele

Table 2  APOE allele distribution among the study population and stages of fibrosis in chronic hepatitis C patients, n (%)

	HCV-patients			Fibrosis stage in CHC patients4
	Chronic (n = 206)	Clearance (n = 93)	P value	F1-F2 (n = 49)	F3-F4 (n = 38)	P value
Genotypes
ε2ε2	2 (1.0)	0	-	0	0	-
ε2ε3	15 (7.4)	8 (8.6)	0.691	5 (10.5)	2 (5.3)	0.400
ε2ε4	2 (1.0)	0	-	0	0	-
ε3ε3	160 (77.5)	64 (68.8)	0.102	29 (59.2)	34 (89.5)	0.001
ε3ε4	26 (12.7)	19 (20.4)	0.080	14 (28.6)	1 (2.6)	0.001
ε4ε4	1 (0.5)	2 (2.2)	0.181	1 (2)	1 (2.6)	0.969
Alleles
ε2	21 (5.1)	8 (4.3)	0.674	4 (5.1)	2 (2.6)	0.603
ε3	361 (87.6)	155 (83.3)	0.158	78 (78.6)	70 (93.4)	0.0222
ε4	30 (7.3)	23 (12.4)	0.0421	16 (16.3)	4 (4)	0.0233
HWE	0.438	0.892	-	0.910	0.286	-

¹ε4 allele was associated with SC OR = 0.55, 95%CI: 0.31-0.98, P = 0.042.

²ε3 allele was associated with severe fibrosis (F3-F4) OR = 2.99, 95%CI: 1.13-7.87, P = 0.021.

³ε4 allele was associated with mild fibrosis (F1-F2) OR = 0.091, 95%CI: 0.01-0.75, P = 0.020.

⁴Liver damage was assessed in 87 chronic hepatitis C patients. CHC: Chronic hepatitis C; HWE: Hardy-Weinberg Equilibrium.